Protara Therapeutics (TARA) Cash from Financing Activities (2014 - 2026)

Protara Therapeutics (TARA) has 13 years of Cash from Financing Activities data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 33.87% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $82.1 million, a 42.03% decrease from a year earlier, with the FY2025 full-year figure at $82.7 million, down 40.86% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $1.1 million, down from $81.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for TARA reached as high as $97.8 million in Q4 2024 and fell as low as -$76000.0 in Q1 2024.
• Historically, Cash from Financing Activities has averaged $18.6 million across 5 years, with a median of $10500.0 in 2025.
• On a YoY basis, Cash from Financing Activities climbed as much as 2376.32% in 2025 and fell as far as 99.98% in 2025.
• Year by year, Cash from Financing Activities stood at -$18000.0 in 2022, then slumped by 50.0% to -$27000.0 in 2023, then jumped by 362503.7% to $97.8 million in 2024, then fell by 17.26% to $81.0 million in 2025, then sank by 98.59% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.1 million in Q1 2026, $81.0 million in Q4 2025, and $13000.0 in Q3 2025.